SPONSOR
Shanghai Henlius Biotech
Total Trials
9
Recruiting
9
Phases
Phase 1, Phase 3, Phase 2, Phase 3, Phase 2
Conditions studied: Solid Tumor and NSCLCGastroesophageal-junction CancerMonoclonal AntibodyGastric CancerHER2-positive Gastric CancerMultiple Myeloma (MM)Advanced or Metastatic Squamous Non-Small Cell Lung CancerSCLCNECHER2-low Hormone Receptor Positive Breast Cancer
Shanghai Henlius Biotech is a clinical research sponsor with 9 registered studies on ClinicalTrials.gov, of which 9 are actively recruiting participants. Research covers conditions including Solid Tumor and NSCLC, Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer.
The trial portfolio spans Phase 1, Phase 3, Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Shanghai Henlius Biotech
How many clinical trials has Shanghai Henlius Biotech sponsored?
ClinicalMetric currently tracks 9 clinical trials sponsored by Shanghai Henlius Biotech, of which 9 are actively recruiting participants. These trials cover conditions including Solid Tumor and NSCLC, Gastroesophageal-junction Cancer, Monoclonal Antibody. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Shanghai Henlius Biotech research focus on?
Shanghai Henlius Biotech clinical trials span Solid Tumor and NSCLC, Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer, and additional conditions. The research pipeline includes Phase 1, Phase 3, Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Shanghai Henlius Biotech clinical trial?
To participate in a Shanghai Henlius Biotech trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Shanghai Henlius Biotech trials with current recruitment status updated daily.
Clinical Trials by Shanghai Henlius Biotech
NCT06210815 Phase 1
Recruiting
A Study of HLX42 in Advanced/Metastatic Solid Tumors
Solid Tumor and NSCLC
NCT06532006 Phase 3
Recruiting
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Gastroesophageal-junction Cancer
NCT07477587 Phase 1
Recruiting
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Multiple Myeloma (MM)
NCT07459751 Phase 2, Phase 3
Recruiting
A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
NCT07416695 Phase 1
Recruiting
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC
SCLC
NCT06832202 Phase 2
Recruiting
A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients
HER2-low Hormone Receptor Positive Breast Cancer
NCT07541534 Phase 1
Recruiting
A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid Tumors
Advanced/Metastatic Solid Tumors
NCT06907615 Phase 2
Recruiting
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer
NCT07106892 Phase 2
Recruiting
Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer
Colorectal Cancer (CRC)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology